share_log

国药现代(600420.SH):恩格列净片获得药品注册证书

Sinopharm Hyundai (600420.SH): Empagliflozin tablets obtained drug registration certificate

Gelonghui Finance ·  Apr 15 05:18

Gelonghui, April 15 | Sinopharm Hyundai (600420.SH) announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for englizine tablets approved and issued by the State Drug Administration. Empagliflozin reduces the ability of the kidneys to recycle glucose back into the bloodstream and excretes sugar from the body through urine, which helps reduce patients' blood sugar levels.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment